{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-380215","form_type":"8-K","ticker":"ATTO","cik":"0002058707","company_name":"Attovia Therapeutics, Inc.","filed_at":"2026-09-02T20:17:18+00:00","discovered_at":"2026-09-02T20:18:12.946407+00:00","generated_at":"2026-09-02T20:18:24.758204+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Attovia Q2 2026 net loss $20.7M; ATTO-1310 proof-of-concept; IPO funds runway to 2030","bullets":["Q2 2026 net loss $20.7M vs $14.4M year ago; R&D $18.9M vs $13.6M; collaboration revenue $0.5M.","Cash $115.1M at 6/30/26; plus $305.4M net IPO proceeds (Aug '26) extends runway into 2030.","ATTO-1310 Phase 1b shows rapid itch relief in chronic pruritus and high-itch AD; full data Q4 2026.","Phase 2 studies in CPUO and high-itch AD planned 1H 2027; Phase 1 for ATTO-2306/1091 also 1H 2027.","IPO gross proceeds $332.4M; board strengthened with John W. Smither appointment."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-380215","json":"https://secwatch.observer/filing/0001193125-26-380215.json","markdown":"https://secwatch.observer/filing/0001193125-26-380215.md","text":"https://secwatch.observer/filing/0001193125-26-380215.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2058707/000119312526380215/0001193125-26-380215-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2058707/000119312526380215/atto-20260902.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-02T20:18:24.758204+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}